Markets 

UK COVID-19 trial finds no benefit of gout drug in hospitalised adults

FILE PHOTO: Health care workers transport a patient at the Royal London Hospital, as the spread of the coronavirus disease (COVID-19) continues, in London, Britain, January 26, 2021. REUTERS/Hannah McKay

(Reuters) – A large British trial has halted enrolments to test gout drug colchicine as a potential treatment for patients hospitalised with COVID-19, after a sub-study of the trial found that the medication did not have any effect on the patients.

An independent panel suggested pausing recruitment of volunteers in the colchicine arm of the trial based on a preliminary analysis, scientists involved in UK’s RECOVERY study said. The study is the world’s largest trial of treatments for hospitalised COVID-19 adults.

Source: Read Full Article

You May Also Like

Indian shares hit record highs as COVID-19 restrictions ease

GRAPHIC-Global active equity funds see inflows after seven years

GM posts 4.8% rise in sales; sees demand picking up in spring